BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions

26 August 2017 (14:47 - 15:00)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor David Kandzari

Piedmont Heart Institute, Atlanta (United States of America)

6 More presentations in this session

Presentation thumbnail

Comparison of titanium-nitride-oxide-coated versus everolimus-eluting stents in acute coronary syndrome

Doctor P. Tonino (Eindhoven, NL)

Presentation thumbnail

A Multicenter, Randomized-Controlled, Blinded Trial of Drug-Eluting vs. Bare Metal Stents in De Novo Saphenous Vein Graft Lesions

Mr E. Brilakis (Minneapolis, US)

Presentation thumbnail

Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized controlled trial

Professor M. Hong (Seoul, KR)

Presentation thumbnail

Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention and Survival in Patients with Type 1 Diabetes Mellitus

Doctor M. Holzmann (Stockholm, SE)

Presentation thumbnail

Five-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Doctor M. Natsuaki (Saga, JP)

Access the full session

Session thumbnail

Late-Breaking Science in PCI 1

The Event

ESC Congress 2017

26 August 2017 14:47 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources